Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

Clinical and Experimental Immunology

Volumn 184, Issue 3, 2016, Pages 265-283

  Wagner, L ^a,e   Klemann, C ^b,c   Stephan, M ^d   Von Horsten S ^e,f  

^a Deutschsprachige Selbsthilfegruppe für Alkaptonurie DSAKU E V   (Germany)

^b Centre of Paediatric Surgery   (Germany)

^c Centre for Paediatrics and Adolescent Medicine   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antigen presentation processing; CD26; Co stimulation; DPP4 activity and or structure homologue proteins (DASH); Signal transduction

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ISOLEUCINE THIAZOLIDIDE; SEPRASE; VILDAGLIPTIN; ADA PROTEIN, HUMAN; ADENOSINE DEAMINASE; CAV1 PROTEIN, HUMAN; CAVEOLIN 1; CHEMOKINE; DPP4 PROTEIN, HUMAN; GELATINASE; ISOENZYME; MEMBRANE PROTEIN; SERINE PROTEINASE; TUMOR MARKER;

ANTIGEN PRESENTATION; ARTHRITIS; ARTICLE; ASTHMA; BREAST CANCER; CELL DIFFERENTIATION; COLON CANCER; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGY; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THYROID CANCER; TRANSGENIC ANIMAL; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; NEOPLASMS; PATHOLOGY; STRUCTURAL HOMOLOGY; T LYMPHOCYTE;

ADENOSINE DEAMINASE; ANTIGEN PRESENTATION; BIOMARKERS, TUMOR; CAVEOLIN 1; CELL DIFFERENTIATION; CHEMOKINES; DIPEPTIDYL PEPTIDASE 4; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY, PROTEIN; T-LYMPHOCYTES;

EID: 84959569564     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12757     Document Type: Article

References (151)

1. Scanlan MJ, Raj BK, Calvo B et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994; 91:5657-61.
2. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267:6140-50.
3. Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002; 299:185-93.
4. Wada K, Yokotani N, Hunter C, Doi K, Wenthold RJ, Shimasaki S. Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci USA 1992; 89:197-201.
5. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J 2003; 373:179-89.
6. Abbott CA, Gorrell MD. The family of CD26/DP IV and related Ectopeptidases. In: Langner J, Ansorge S, eds. Ectopeptidases. New York: Kluwer Academic/Plenum Publishers, 2002:171-95.
7. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005; 108:277-92.
8. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40:209-94.
9. Klemann C, Wagner L, Von Horsten S, Stephan M. Cut to the chase: CD26/dipeptidyl peptidase-4 (DPP-4)'s entanglement in the immune system, a review. Clin Exp Immunol 2015; accepted.
10. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011; 71:1441-67.
11. Wagner L, Wolf R, Zeitschel U et al. Proteolytic degradation of neuropeptide Y (NPY) from head to toe novel NPY-cleaving enzymes and revealed potential drug interactions. J Neurochem 2015; 135:1019-37.
12. Frerker N, Wagner L, Wolf R et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 2007; 28:257-68.
13. Yu DM, Yao TW, Chowdhury S et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010; 277:1126-44.
14. Keane FM, Nadvi NA, Yao TW, Gorrell MD. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J 2011; 278:1316-32.
15. Edosada CY, Quan C, Tran T et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 2006; 580:1581-6.
16. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107:1397-404.
17. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. Alpha2-antiplasmin: potential therapeutic roles in fibrin survival and removal. Curr Med Chem Cardiovasc Hematol Agents 2004; 2:303-10.
18. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates [alpha]2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103:3783-8.
19. Aertgeerts K, Ye S, Tennant MG et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004; 13:412-21.
20. Ghersi G, Dong H, Goldstein LA et al. Seprase-dPPIV association and prolyl peptidase and gelatinase activities of the protease complex. Adv Exp Med Biol 2003; 524:87-94.
21. Milner JM, Kevorkian L, Young DA et al. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 2006; 8:R23.
22. Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen WT. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006; 66:4652-61.
23. Kotackova L, Balaziova E, Sedo A. Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol (Praha) 2009; 55:77-84.
24. Busek P, Mali kR, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004; 36:408-21.
25. Lessard J, Pelletier M, Biertho L et al. Characterization of dedifferentiating human mature adipocytes from the visceral and subcutaneous fat compartments: fibroblast-activation protein alpha and dipeptidyl peptidase 4 as major components of matrix remodeling. PLoS One 2015; 10:e0122065.
26. Henry LR, Lee HO, Lee JS et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13:1736-41.
27. Artym VV, Kindzelskii AL, Chen WT, Petty HR. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis 2002; 23:1593-601.
28. Niedermeyer J, Kriz M, Hilberg F et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20:1089-94.
29. Waldele S, Koers-Wunrau C, Beckmann D et al. Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis. Arthritis Res Ther 2015; 17:12.
30. Nemunaitis J, Vukelja SJ, Richards D et al. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest 2006; 24:553-61.
31. Bjelke JR, Christensen J, Nielsen PF et al. Dipeptidyl peptidase 8 and 9 specificity and molecular characterization compared to dipeptidyl peptidase IV. Biochem J 2006; 396:391-6.
32. Yu LR, Zhu Z, Chan KC, Issaq HJ, Dimitrov DS, Veenstra TD. Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 2007; 6:4150-62.
33. Ajami K, Pitman MR, Wilson CH et al. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 2008; 582:819-25.
34. Wilson CH, Indarto D, Doucet A et al. Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism. J Biol Chem 2013; 288:13936-49.
35. Yu DM, Ajami K, Gall MG et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem 2009; 57:1025-40.
36. Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta 2004; 1679:18-28.
37. Zhang H, Chen Y, Wadham C, McCaughan GW, Keane FM, Gorrell MD. Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal adhesion kinase and paxillin. Biochim Biophys Acta 2015; 1853:470-80.
38. Justa-Schuch D, Moller U, Geiss-Friedlander R. The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus. Cell Mol Life Sci 2014; 71:3611-26.
39. Geiss-Friedlander R, Parmentier N, Moller U, Urlaub H, Van den Eynde BJ, Melchior F. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 2009; 284:27211-9.
40. Zhang H, Maqsudi S, Rainczuk A et al. Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis. FEBS J 2015; 282:3737-57.
41. Yao TW, Kim WS, Yu DM et al. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signalling. Mol Cancer Res 2011; 9:948-59.
42. Zhang H, Chen Y, Keane FM, Gorrell MD. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9. Mol Cancer Res 2013; 11:1487-96.
43. Gall MG, Chen Y, Vieira de Ribeiro AJ et al. Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality. PLOS ONE 2013; 8:e78378.
44. Schade J, Stephan M, Schmiedl A et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 2008; 56:147-55.
45. Rohnert P, Schmidt W, Emmerlich P et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation 2012; 9:44.
46. Dubois V, Lambeir AM, Vandamme S et al. Dipeptidyl peptidase 9 (DPP9) from bovine testes: identification and characterization as the short form by mass spectrometry. Biochim Biophys Acta 2010; 1804:781-8.
47. Maes MB, Dubois V, Brandt I et al. Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol 2007; 81:1252-7.
48. Reinhold D, Goihl A, Wrenger S et al. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. Clin Chem Lab Med 2009; 47:268-74.
49. Eager RM, Cunningham CC, Senzer NN et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer 2009; 9:263.
50. Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 2015; 6:387.
51. Waumans Y, Baerts L, Kehoe K et al. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 2015; 6:387.
52. Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54:2988-94.
53. Wu JJ, Tang HK, Yeh TK et al. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol 2009; 78:203-10.
54. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010; 118:31-41.
55. Bank U, Heimburg A, Wohlfarth A et al. Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem 2011; 392:169-87.
56. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008; 10:1057-61.
57. Yu DM, Wang XM, McCaughan GW, Gorrell MD. Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS J 2006; 273:2447-60.
58. Park J, Knott HT, Navdi NA et al. Reversible inactivation of human dipeptidyl peptidases 8 and 9 by oxidation. Open Enzym Inhib J 2008; 1:52-60.
59. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003; 10:19-25.
60. Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007; 66:160-71.
61. Zagha E, Ozaita A, Chang SY et al. Dipeptidyl peptidase 10 modulates Kv4-mediated A-type potassium channels. J Biol Chem 2005; 280:18853-61.
62. Chen T, Ajami K, McCaughan GW, Gai WP, Gorrell MD, Abbott CA. Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. Biochim Biophys Acta 2006; 1764:33-43.
63. Strop P, Bankovich AJ, Hansen KC, Garcia KC, Brunger AT. Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family. J Mol Biol 2004; 343:1055-65.
64. van Es MA, van Vught PW, van Kempen G, Blauw HM, Veldink JH, van den Berg LH. Dpp6 is associated with susceptibility to progressive spinal muscular atrophy. Neurology 2009; 72:1184-5.
65. Daoud H, Valdmanis PN, Dion PA, Rouleau GA. Analysis of DPP6 and FGGY as candidate genes for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11:389-91.
66. Tanaka S, Syu A, Ishiguro H et al. DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics J 2013; 13:27-34.
67. Postema PG, Christiaans I, Hofman N et al. Founder mutations in the Netherlands: familial idiopathic ventricular fibrillation and DPP6. Neth Heart J 2011; 19:290-6.
68. Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. Curr Opin Genet Dev 2009; 19:279-82.
69. Bezerra GA, Dobrovetsky E, Seitova A, Dhe-Paganon S, Gruber K. Crystallization and preliminary X-ray diffraction analysis of human dipeptidyl peptidase 10 (DPPY), a component of voltage-gated potassium channels. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012; 68:214-7.
70. Sedo A, Malik R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta 2001; 1550:107-16.
71. Barinka C, Rinnova M, Sacha P et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002; 80:477-87.
72. Durinx C, Lambeir AM, Bosmans E et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000; 267:5608-13.
73. Friedrich D, Hoffmann T, Bar J et al. Does human attractin have DP4 activity? Biol Chem 2007; 388:155-62.
74. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 1996; 156:1714-21.
75. Araki H, Li Y, Yamamoto Y et al. Purification, molecular cloning, and immunohistochemical localization of dipeptidyl peptidase II from the rat kidney and its identity with quiescent cell proline dipeptidase. J Biochem (Tokyo) 2001; 129:279-88.
76. Leiting B, Pryor KD, Wu JK et al. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 2003; 371:525-32.
77. Chiravuri M, Huber BT. Aminodipeptidase inhibitor-induced cell death in quiescent lymphocytes: a review. Apoptosis 2000; 5:319-22.
78. Maes MB, Scharpe S, De Meester I. Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 2007; 380:31-49.
79. Chiravuri M, Lee H, Mathieu SL, Huber BT. Homodimerization via a leucine zipper motif is required for enzymatic activity of quiescent cell proline dipeptidase. J Biol Chem 2000; 275:26994-9.
80. Mentlein R, Struckhoff G. Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem 1989; 52:1284-93.
81. Brandt I, Lambeir AM, Maes MB, Scharpe S, De Meester I. Peptide substrates of dipeptidyl peptidases. Adv Exp Med Biol 2006; 575:3-18.
82. Mele DA, Bista P, Baez DV, Huber BT. Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle 2009; 8:2425-34.
83. Bista P, Mele DA, Baez DV, Huber BT. Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Mol Immunol 2008; 45:3618-23.
84. Maes MB, Martinet W, Schrijvers DM et al. Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 2006; 72:70-9.
85. Gossrau R, Lojda Z. Study on dipeptidylpeptidase II (DPP II). Histochemistry 1980; 70:53-76.
86. Danilova OV, Tai AK, Mele DA et al. Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity. Endocrinology 2009; 150:5240-8.
87. Bezerra GA, Dobrovetsky E, Dong A et al. Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases. PLOS ONE 2012; 7:e43019.
88. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82:53-73.
89. Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008; 13:2299-310.
90. Vora KA, Porter G, Peng R et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 2009; 10:1.
91. Ohnuma K, Hatano R, Aune TM et al. Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes. J Immunol 2015; 194:3697-712.
92. Hatano R, Ohnuma K, Otsuka H et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol 2015; 194:960-72.
93. Salgado FJ, Lojo J, Alonso-Lebrero JL et al. A role for IL-12 in the regulation of T cell plasma membrane compartmentation. J Biol Chem 2003; 278:24849-57.
94. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009; 30:600-7.
95. Yazbeck R, Howarth GS, Butler RN, Geier MS, Abbott CA. Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis. J Cell Physiol 2011; 226:3219-24.
96. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999; 20:367-75.
97. Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 2008; 13:6850-8.
98. Bauer S, Jendro MC, Wadle A et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8:R171.
99. Silva AP, Cavadas C, Baisse-Agushi B, Spertini O, Brunner HR, Grouzmann E. NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC. Regul Pept 2003; 116:71-9.
100. Straub RH, Grum F, Strauch U et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 2008; 57:911-21.
101. Marguet D, Baggio L, Kobayashi T et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97:6874-9.
102. El YM, Vaugeois JM, Marguet D et al. Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity. Behav Brain Res 2006; 171:279-85.
103. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003; 33:1519-27.
104. Karl T, Chwalisz WT, Wedekind D et al. Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (dipeptidyl-peptidase IV; CD26) gene in rats. Regul Pept 2003; 115:81-90.
105. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122:531-44.
106. Nagakura T, Yasuda N, Yamazaki K et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001; 284:501-6.
107. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH. The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 1996; 45:1335-41.
108. Karl T, Hoffmann T, Pabst R, Von Horsten S. Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol Behav 2003; 80:123-34.
109. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298:779-84.
110. Laconi S, Pillai S, Porcu PP, Shafritz DA, Pani P, Laconi E. Massive liver replacement by transplanted hepatocytes in the absence of exogenous growth stimuli in rats treated with retrorsine. Am J Pathol 2001; 158:771-7.
111. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997; 19:15-24.
112. Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BP. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003; 102:641-8.
113. Frerker N, Raber K, Bode F et al. Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clin Chem Lab Med 2009; 47:275-87.
114. Wang Z, Grigo C, Steinbeck J, Von Horsten S, Amann K, Daniel C. Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 2014; 57:109-17.
115. Simeoni L, Rufini A, Moretti T, Forte P, Aiuti A, Fantoni A. Human CD26 expression in transgenic mice affects murine T-cell populations and modifies their subset distribution. Hum Immunol 2002; 63:719-30.
116. Hough RB, Lengeling A, Bedian V, Lo C, Bucan M. Rump white inversion in the mouse disrupts dipeptidyl aminopeptidase-like protein 6 and causes dysregulation of Kit expression. Proc Natl Acad Sci USA 1998; 95:13800-5.
117. Mele DA, Sampson JF, Huber BT. Th17 differentiation is the default program for DPP2-deficient T-cell differentiation. Eur J Immunol 2011; 41:1583-93.
118. Augustyns K, Van der Veken P, Senten K, Haemers A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem 2005; 12:971-98.
119. Jiaang WT, Chen YS, Hsu T et al. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett 2005; 15:687-91.
120. Chen SJ, Jiaang WT. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein. Curr Top Med Chem 2011; 11:1447-63.
121. Van der Veken P, Haemers A, Augustyns K. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. Curr Top Med Chem 2007; 7:621-35.
122. Van Goethem S, Van der Veken P, Dubois V et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. Bioorg Med Chem Lett 2008; 18:4159-62.
123. Hoffmann T, Demuth H-U. Therapeutic strategies exploiting DP IV inhibition - target disease: type 2 diabetes. In: Langner J, Ansorge S, eds. Ectopeptidases. New York, USA: Kluwer Academic/Plenum Publishers, 2002:259-78.
124. Bank U, Tadje J, Helmuth M et al. Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis. Adv Exp Med Biol 2006; 575:143-53.
125. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012; 188:5438-47.
126. Danilov AV, Danilova OV, Brown JR, Rabinowitz A, Klein AK, Huber BT. Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol 2010; 38:1167-77.
127. Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev 2014; 30:646-53.
128. Ospelt C, Mertens JC, Jungel A et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010; 62:1224-35.
129. Tanswell P, Garin-Chesa P, Rettig WJ et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001; 51:177-80.
130. Sato K, Dang NH. CD26: a novel treatment target for T-cell lymphoid malignancies? [Review]. Int J Oncol 2003; 22:481-97.
131. Fujimoto N, Ohnuma K, Aoe K et al. Clinical significance of soluble CD26 in malignant pleural mesothelioma. PLOS ONE 2014; 9:e115647.
132. Wilson CH, Abbott CA. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol 2012; 41:919-32.
133. Weiss ST, Raby BA. Asthma genetics 2003. Hum Mol Genet 2004; 13:R83-9.
134. Busso N, Wagtmann N, Herling C et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005; 166:433-42.
135. Saito T, Ohnuma K, Suzuki H et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract 2013; 102:e8-12.
136. Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 2015; 74:1968-75.
137. Jiang L, Yin J, Ye L et al. Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans. Arthritis Rheumatol 2014; 66:1121-32.
138. Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem 1989; 35:1016-8.
139. Bjelke JR, Kanstrup AB, Rasmussen HB. Selectivity among dipeptidyl peptidases of the s9b family. Cell Mol Biol (Noisy-le-Grand) 2006; 52:3-7.
140. Davoodi J, Kelly J, Gendron NH, MacKenzie AE. The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 2007; 7:2300-10.
141. Canneva F, Golub Y, Distler J et al. DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. Psychoneuroendocrinology 2015; 53:195-206.
142. Guieu R, Fenouillet E, Devaux C et al. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain Res 2006; 166:279-85.
143. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 2003; 52:81-6.
144. Drucker DJ, Boushey RP, Wang F, Hill ME, Brubaker PL, Yusta B. Biologic properties and therapeutic potential of glucagon-like peptide-2. JPEN J Parenter Enteral Nutr 1999; 23:S98-100.
145. Conarello SL, Li Z, Ronan J et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100:6825-30.
146. Lautar SL, Rojas C, Slusher BS et al. DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice. Brain Res 2005; 1048:177-84.
147. Donahue RN, Duncan BB, Fry TJ et al. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. Vaccine 2014; 32:3223-31.
148. Thielitz A, Reinhold D, Vetter R et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007; 127:1042-51.
149. Zhang Y, Zhang X, Liu H, Cai S, Wu B. Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPalpha-based doxorubicin prodrug: formulation and pharmacokinetic evaluation. Int J Nanomedicine 2015; 10:1625-36.
150. Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ. Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 2010; 34:1637-46.
151. Argyrakopoulou G, Doupis J. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Adv Ther 2009; 26:272-80.